Cantex Pharmaceuticals announced the FDA issued a “Study May Proceed” letter for the Phase 2 clinical trial to assess the safety and therapeutic effect of azeliragon in patients with newly diagnosed unmethylated glioblastoma treated with standard of care radiation therapy....
Cantex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma....
Cantex Pharmaceuticals, Inc. today announced that Chimerix, Inc. (NASDAQ:CMRX), worldwide licensee of Cantex’s DSTAT investigational product, yesterday reported promising results of the first cohort of patients hospitalized with COVID-19-associated Acute Lung Injury (ALI)...
Cantex Pharmaceuticals, Inc. today announced that Chimerix, Inc., to whom it licensed worldwide rights for the development and commercialization of its lead product, CX-01 (now known as DSTAT) has initiated a Phase 2/3 study of DSTAT in COVID-19 patients with acute lung injury (ALI)...
Chimerix (NASDAQ: CMRX), today announced the completion of an exclusive worldwide license of CX-01 from Cantex Pharmaceuticals, Inc. Chimerix intends to move quickly into Phase 3 development of CX-01 for the treatment of Acute Myeloid Leukemia (AML) in the first-line setting. CX-01 has received Fast Track and Orphan Drug Designations...